Alimera Sciences Profile

USD 0.04  3.7%

Sale by Myers C Daniel of 26450 shares of Alimera Sciences

Alimera Sciences insider trading alert for sale of common stock by Myers C Daniel, CEO, on September 16, 2018. This event was filed by Alimera Sciences Inc with SEC on 2018-01-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Alimera Sciences Summary

Alimera Sciences (ALIM) is traded on BATS Exchange in USA. It is located in GEORGIA U.S.A and employs 118 people. Alimera Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 61.61 M. Alimera Sciences conducts business under Healthcare sector and is part of Drug Manufacturers - Major industry. This company has 70.04 M outstanding shares of which 768.3 K shares are presently shorted by private and institutional investors with about 6.84 trading days to cover. Alimera Sciences currently holds about 16.69 M in cash with (14.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Check Alimera Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Alimera Sciences Target Price Odds Analysis

Odds Below 1.04HorizonTargetOdds Above 1.04
35.57%30 days 1.04 64.20%
Based on normal probability distribution, the odds of Alimera Sciences to move above current price in 30 days from now is about 64.2% (This Alimera Sciences probability density function shows the probability of Alimera Sciences Stock to fall within a particular range of prices over 30 days) .

Alimera Sciences Top Holders

Alimera Sciences Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Stonepine Capital Management LlcCommon Shares7 M6.8 M
Armistice Capital LlcCommon Shares6.9 M6.8 M
View Alimera Sciences Diagnostics

Alimera Sciences Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Alimera Sciences Key Fundamentals

Alimera Sciences Against Markets

Alimera Sciences Current Ratings

Alimera Sciences 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Alimera Sciences are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug Manufacturers - Major classification in USA and traded on BATS Exchange. It employs 118 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Alimera Sciences SEC Filings
Alimera Sciences SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAlimera Sciences
President CEO, DirectorDaniel MyersView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Drug Manufacturers - Major
InstrumentUSA Stock View All
RegionNorth America
Business Address6120 Windward Parkway
ExchangeBATS Exchange
CIK Number0001267602
IndustryDrug Manufacturers - Major
Phone678 990 5740
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestJuly 13, 2018

Alimera Sciences Directors

Alimera Sciences Corporate Directors

James Largent Independent Director
Peter Pizzo Independent Director
Calvin Roberts Independent Director
Check also Trending Equities. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.